Merck Chases $6B Terns Pharma Deal to Boost Cancer Pipeline — Is Keytruda’s Expiry Driving the Panic?

Merck is reportedly nearing a $6.0 billion all-cash acquisition of Terns Pharmaceuticals to bolster its oncology pipeline ahead of Keytruda's potential 2028 patent expiry. Keytruda generated approximately $31.7 billion in 2025 and accounts for nearly half of Merck's sales, so the deal would add early-stage CML and NASH/obesity assets to diversify future oncology revenue. The reports are unconfirmed and neither company has commented; Wall Street consensus is a Moderate Buy (13 Buys, 6 Holds) with an average price target of $131.42, implying ~13% upside. The rumor is material enough to move MRK shares and is strategically important for Merck's long-term oncology franchise planning.

Analysis

Management actions to bulk-up early-stage assets are best read as optionality purchases rather than immediate revenue drivers: the practical effect is to re-price medium-term R&D runway and shift investor focus from single-molecule concentration risk to portfolio convexity. That re-pricing compresses implied volatility in the acquirer's equity but raises it for the small-cap targets, creating exploitable dispersion between a large, liquid acquirer and an illiquid biotech.

Second-order winners include contract manufacturers and biologics CDMOs who will see incremental demand for fill/finish and scale-up services if the buyer presses multiple early assets toward clinic; losers are mid-size oncology-focused peers who must either match pace via expensive deals or cede share in BD/early discovery talent. Payer dynamics will also shift incrementally: acquiring multiple indications compounds evidence-generation costs and forces tougher launch sequencing, which can depress peak pricing assumptions used by sell-side models.

Key risks are execution and binary clinical outcomes: integration slippage, milestone shortfalls, or regulatory setbacks can erase premiums quickly — these are 3–24 month risks depending on trial stage. Near-term market moves will be dominated by deal-confirmation flow and any attached financing; medium-term returns hinge on Phase II/III readouts and whether the buyer converts optionality into differentiated clinical data.

Key Decisions for Investors

• Event arb (speculative): Buy TERN equity sized 1–2% NAV as an acquirer-target exposure; set a tactical take-profit at +30–50% on confirmation and a hard stop at -20% if no definitive outcome within 30 calendar days. Rationale: small-cap takeover spreads typically compress rapidly on deal certainty; downside is high if the rumor breaks.
• Core hedge-adjusted long: Accumulate MRK via Jan-2029 LEAP calls (2–3 year horizon) sized 2–4% NAV, financed by selling 3–6 month covered calls to trim cost. Target 25–40% IRR if pipeline optionality materializes; downside limited to premium paid (use position sizing to cap NAV hit to 3–4%).
• Relative value pair: Long MRK / short BMY (0.6–0.8x size) over 6–18 months to express conviction in superior pipeline replenishment execution. Target asymmetric payoff: 12–20% absolute upside on the pair if MRK derisks assets vs 10–15% downside in adverse clinical scenarios — hedge with cheap put protection for outsized trial risk.
• Tactical protection: Ahead of near-term corporate/BD announcements, buy a 4–8 week MRK 5–10% OTM put spread to cap event risk at a defined cost (size 1–2% NAV). This limits single-event tail exposure while retaining upside from successful integration and pipeline news.